MedTech Terms
    The authoritative reference
    All terms
    Investment & FinanceStartup Lifecycle

    Non-Dilutive Funding

    Capital that does not require giving up equity, such as grants or debt.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Non-dilutive funding includes government grants (NIH SBIR/STTR, BARDA, ARPA-H), foundation grants, venture debt, revenue-based financing, and strategic milestone payments - capital that does not require issuing equity.
    What the regulation says
    While non-dilutive funding itself is not directly regulated, the use of such funds in MedTech is subject to the same regulatory requirements as any other funding source (e.g., FDA 21 CFR Part 820 for Quality System Regulation). Funding from government sources like NIH or BARDA often comes with specific reporting and compliance obligations related to project milestones and expenditures, distinct from general MedTech regulations.

    What this means in practice

    SBIR Phase I/II grants are a common MedTech bridge from idea to first equity round. Venture debt typically arrives after a Series B and extends runway with minimal dilution.

    Examples

    • A MedTech startup receives an NIH SBIR grant to develop a novel diagnostic algorithm, which allows them to fund early-stage research and development without giving up equity before seeking venture capital.
    • A mature medical device company uses venture debt to expand its manufacturing capabilities for an existing Class II device, avoiding shareholder dilution while meeting increased market demand.
    • A small MedTech firm secures a BARDA contract to accelerate the development of a therapeutic device for pandemic preparedness, ensuring rapid prototyping and clinical trials without immediate equity financing.
    Common pitfalls
    • •Confusing non-dilutive funding with a lack of financial oversight, as all financial activities within a MedTech company are subject to scrutiny during audits.
    • •Underestimating the administrative burden and reporting requirements associated with government grants, which can divert resources from core MedTech development activities.
    • •Failing to allocate non-dilutive funds appropriately to ensure compliance with quality system requirements (e.g., ISO 13485) throughout the product lifecycle.
    • •Assuming that non-dilutive funding implies less scrutiny on the scientific or technical merit of the MedTech innovation, as these funds often have rigorous review processes.

    Frequently asked questions

    The source of funding generally does not directly impact the content or review process of regulatory submissions, such as FDA 510(k) or PMA applications. However, strong financial backing, regardless of source, can demonstrate a company's ability to support post-market surveillance and other regulatory obligations.
    Grouped by theme

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    NIH·1SVB·1PitchBook·1
    1. 1
      NIH SBIR/STTR
      Verified
      NIHseed.nih.gov
    2. 2
      Silicon Valley Bank - Healthcare Reports
      Verified
      SVBsvb.com
    3. 3
      PitchBook - MedTech Coverage
      Verified
      PitchBookpitchbook.com

    Inline markers like [1] jump to the matching reference above.